Barbara Willandt1, Janneke G Langendonk2, Katharina Biermann3, Wouter Meersseman4, François D'Heygere5, Christophe George5, Chris Verslype1, Diethard Monbaliu6, David Cassiman7,8. 1. Department of Hepatology, University Hospitals Leuven, Herestraat 49, 3000, Leuven, Belgium. 2. Department of Internal Medicine, Center for Lysosomal and Metabolic Diseases, Nederlands Porphyria Center, Erasmus MC, Rotterdam, The Netherlands. 3. Department of Pathology, Erasmus MC, Rotterdam, The Netherlands. 4. Metabolic Center, University Hospitals Leuven, Leuven, Belgium. 5. Department of Gastroenterology, AZ Groeninge, Kortrijk, Belgium. 6. Abdominal Transplantation Unit, University Hospitals Leuven, Leuven, Belgium. 7. Department of Hepatology, University Hospitals Leuven, Herestraat 49, 3000, Leuven, Belgium. david.cassiman@uzleuven.be. 8. Metabolic Center, University Hospitals Leuven, Leuven, Belgium. david.cassiman@uzleuven.be.
Abstract
Acute intermittent porphyria (AIP) is an autosomal dominant disorder of heme biosynthesis due to a mutation in the porphobilinogen deaminase gene. The mutation causes a deficiency in the porphobilinogen deaminase enzyme, thereby causing an accumulation of heme precursors (δ-aminolevulinic acid and porphobilinogen). These neurotoxic heme precursors elicit acute neurovisceral attacks, which can be treated with heme-arginate infusions. Some patients require heme-arginate infusions on a regular basis for many years, which ultimately leads to an iron accumulation (increased serum ferritin and iron accumulation in the liver, spleen, and bone marrow on MRI). We report three AIP patients, who developed iron accumulation (with serum ferritin up to 7,850 microgram/liter) due to multiple heme-arginate infusions. We report for the first time that the iron accumulation in these patients was associated with fibrosis on liver histology. CONCLUSION: Regular heme-arginate treatment in AIP does not only lead to increased serum ferritin but may also induce liver fibrosis. This should be taken into account, when weighing the risks and benefits of repeated heme-arginate treatment against the risk and benefits of treating refractory AIP by liver transplantation.
Acute intermittent porphyria (AIP) is an autosomal dominant disorder of heme biosynthesis due to a mutation in the porphobilinogen deaminase gene. The mutation causes a deficiency in the porphobilinogen deaminase enzyme, thereby causing an accumulation of heme precursors (δ-aminolevulinic acid and porphobilinogen). These neurotoxic heme precursors elicit acute neurovisceral attacks, which can be treated with heme-arginate infusions. Some patients require heme-arginate infusions on a regular basis for many years, which ultimately leads to an iron accumulation (increased serum ferritin and iron accumulation in the liver, spleen, and bone marrow on MRI). We report three AIPpatients, who developed iron accumulation (with serum ferritin up to 7,850 microgram/liter) due to multiple heme-arginate infusions. We report for the first time that the iron accumulation in these patients was associated with fibrosis on liver histology. CONCLUSION: Regular heme-arginate treatment in AIP does not only lead to increased serum ferritin but may also induce liver fibrosis. This should be taken into account, when weighing the risks and benefits of repeated heme-arginate treatment against the risk and benefits of treating refractory AIP by liver transplantation.
Authors: Marko Siegesmund; Anne-Moniek van Tuyll van Serooskerken; Pamela Poblete-Gutiérrez; Jorge Frank Journal: Best Pract Res Clin Gastroenterol Date: 2010-10 Impact factor: 3.043
Authors: Manisha Balwani; Bruce Wang; Karl E Anderson; Joseph R Bloomer; D Montgomery Bissell; Herbert L Bonkovsky; John D Phillips; Robert J Desnick Journal: Hepatology Date: 2017-09-04 Impact factor: 17.425
Authors: Chaudry Nasir Majeed; Christopher D Ma; Ted Xiao; Sean Rudnick; Herbert L Bonkovsky Journal: Drug Des Devel Ther Date: 2022-06-16 Impact factor: 4.319
Authors: Paolo Ventura; Herbert L Bonkovsky; Laurent Gouya; Paula Aguilera-Peiró; D Montgomery Bissell; Penelope E Stein; Manisha Balwani; D Karl E Anderson; Charles Parker; David J Kuter; Susana Monroy; Jeeyoung Oh; Bruce Ritchie; John J Ko; Zhaowei Hua; Marianne T Sweetser; Eliane Sardh Journal: Liver Int Date: 2021-11-16 Impact factor: 8.754
Authors: Rochus A Neeleman; Margreet A E M Wagenmakers; Rita H Koole-Lesuis; G Sophie Mijnhout; J H Paul Wilson; Edith C H Friesema; Janneke G Langendonk Journal: J Inherit Metab Dis Date: 2018-04-19 Impact factor: 4.982
Authors: Helene J Bustad; Juha P Kallio; Marta Vorland; Valeria Fiorentino; Sverre Sandberg; Caroline Schmitt; Aasne K Aarsand; Aurora Martinez Journal: Int J Mol Sci Date: 2021-01-12 Impact factor: 5.923